Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 2, 2010, Pages 128-134

  Giardino, Edward C ^a   Haertlein, Barbara J ^a   De Garavilla, Lawrence ^a   Costanzo, Michael J ^a   Damiano, Bruce P ^a   Andrade Gordon, Patricia ^a   Maryanoff, Bruce E ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antithrombotic; Cooperativity; Factor Xa; Inhibitor; Thrombin

Indexed keywords

[N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; N [2 [[(AMINOIMINOMETHYL)AMINO]OXY]ETHYL] 6 METHYL 3 [[(3 METHYLPHENYL)SULFONYL]AMINO] 2 OXO 1(2H) PYRIDINEACETAMIDE; RWJ 445167; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY INJURY; CONTROLLED STUDY; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; ELECTRIC INJURY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD COAGULATION; DRUG SYNERGISM; FACTOR XA; GUANIDINES; HUMANS; MALE; NAPHTHALENES; PIPECOLIC ACIDS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; THROMBIN;

EID: 76449108473     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283358100     Document Type: Article

References (34)

1. Gresele P, Giancarlo A. Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci 2002; 23:25-32.
2. Prezelj A, Anderluh PS, Peternel L, Urleb U. Recent advances in serine protease inhibitors as anticoagulants. Curr Pharm Design 2007; 13:287-312.
3. Brogan GX. Update on acute coronary syndromes and implications for therapy. Expert Opin Investig Drugs 2003; 12:1971-1983.
4. Bergqvist D. New approaches to prevention of deep vein thrombosis. Thromb Haemost 1997; 78:684-688.
5. Davie EW, Fugikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30:10363-10370.
6. Linkins L-A, Weitz JI. Pharmacology and clinical potential of direct thrombin inhibitors. Curr Pharm Des 2005; 11:3877-3884.
7. Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic. Curr Top Med Chem 2005; 5:1677-1695.
8. Scarborough RM, Pandey A, Zhang X. Small molecule anticoagulant/ antithrombotic agents. Annu Rep Med Chem 2005; 40:85-101.
9. Casimiro-Garcia A, Dudley DA, Heemstra RJ, Filipski KJ, Bigge CF, Edmunds JJ. Progress in the discovery of factor Xa inhibitors. Expert Opin Ther Pat 2006; 16:119-145.
10. Alexander JH, Singh KP. Inhibition of factor Xa: a potential target for the development of new anticoagulants. Am J Cardiovasc Drugs 2005; 5:279-290.
11. Sorbera LA, Bozzo J, Castaner J. Dabigatran/dabigatran etexilate: prevention of DVT prevention of ischemic stroke thrombin inhibitor. Drugs Future 2005; 30:877-885.
12. Escolar G, Villalta J, Casals F, Bozzo J, Serradell N, Bolos J. Rivaroxaban: factor Xa inhibitor anticoagulant. Drugs Future 2006; 31:484-493.
13. Kranjc A, Kikelj D. Dual inhibitors of the blood coagulation enzymes. Curr Med Chem 2004; 11:2535-2547.
14. Young RJ, Brown D, Burns-Kurtis CL, Chan C, Convery MA, Hubbard JA, et al. Selective and dual action orally active inhibitors of thrombin and factor Xa. Bioorg Med Chem Lett 2007; 17:2927-2930.
15. Dönnecke D, Schweinitz A, Stürzebecher A, Steinmetzer P, Schuster M, Stürzebecher U, et al. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3. Bioorg Med Chem Lett 2007; 17:3322-3329.
16. Meddahi S, Samama MM. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone? Blood Coagul Fibrinol 2009; 20:207-214.
17. Gould WR, McClanahan TB, Welch KM, Baxi SM, Saiya-Cork K, Chi L, et al. Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro. J Thromb Haemost 2006; 4:834-841.
18. Maryanoff BE, McComsey DF, Costanzo MJ, Yabut SC, Lu T, Player MR, et al. Exploration of potential prodrugs of RWJ-445167, an oxyguanidinebased dual inhibitor of thrombin and factor Xa. Chem Biol Drug Design 2006; 68:29-36.
19. Escolar G, Bozzo J, Maragall S. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions. Drugs Today 2006; 42:223-236.
20. Hirayama F, Koshio H, Katayama N, Kurihara H, Taniuchi Y, Sato K, et al. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor. Bioorg Med Chem 2002; 10:1509-1523.
21. Hirayama F, Koshio H, Matsumoto Y, Kawasaki T, Kaku S, Yanagisawa I. Preparation of novel N-imidoyl-[p-[(amidinonaphthylmethyl)amino]phenoxy]- piperidine derivatives and analogs as blood platelet aggregation inhibitors. PCT Int Appl 1996; WO 9616940 (EP 0798295A1).
22. Lu T, Tomczuk BE, Markotan TP, Siedem C. Preparation of N-[(oxopyridinylacetamido)-alkoxy] guanidines and analogs as protease inhibitors. PCT Int Appl 1999; WO 9926926.
23. Williams JW, Morrison JF. The kinetics of reversible tight-binding inhibition. Meth Enzymol 1979; 63:437-467.
24. Carmeliet P, Moons L, Stassen JM, De Mol M, Bouche A, van den Oord JJ, et al. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol 1997; 150:761-776.
25. Abboud MA, Needle SJ, Burns-Kurtis CL, Valocik RE, Koster PF, Amour AJ, et al. Antithrombotic potential of GW813893: a novel, orally active, activesite directed factor Xa inhibitor. J Cardiovasc Pharmacol 2008; 52:66-71.
26. Rebello SS, Miller BV, Basler GC, Lucchesi BR. CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol 1997; 29:240-249.
27. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1995; 75:12B- 17B.
28. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 1998; 82:12-18.
29. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 2002; 105:1004-1011.
30. Vlasuk GP. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulant factor Xa. Biochemistry 1990; 291:11095-11100.
31. Cooper DN, Millar DS, Wacey A, Pemberton S, Tuddenham EGD. Inherited factor X deficiency. Molecular genetics and pathophysiology. Thromb Haemost 1997; 78:161-172. (Pubitemid 27289235)
32. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78:412-421.
33. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995; 92:962-967.
34. Giardino EC, Costanzo MJ, Kauffman JA, Li QS, Maryanoff BE, Andrade- Gordon P. Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor. Thromb Res 2000; 98:83-93.